National Institute of Allergy and Infectious Diseases
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

Radiation Countermeasures
 Program
 Research Areas
  Countermeasures
  Radiation Biodosimetry
 Resources
 Funding
 Summaries and Publications
 Congressional Testimonies


Medical Countermeasures Against Radiological and Nuclear Threats

Radiation Biodosimetry Development Program

Important Links

Food and Drug Administration (FDA): Center for Devices and Radiological Health (CDRH) Medical Device Innovation Initiative (May 22, 2006)

Meetings

NIAID/CMCR Workshop on the FDA Pre-Market Regulatory Process: Applications to Technologies for Radiation Biodosimetry After a Large-Scale Radiological Incident, March 27th, 2006, Bethesda, MD

March 27, 2006 Meeting Slides

The FDA Pre-Market Regulatory Process(PDF)
Presented by: Mary Pastel, Associate Director for Advanced In Vitro Diagnostics, Office of In Vitro Diagnostic Device Evaluation and Safety and Office of Science and Engineering Laboratories, CDRH, FDA

Pre-IDE Processing (PDF)
Presented by: Sousan Altaie, Scientific Policy Advisor, Office of In Vitro Diagnostic Device Evaluation and Safety, CDRH, FDA

Data Analysis: Software and Statistic(PDF)
Presented by: Estelle Russek-Cohen, Team Leader and Mathematical Statistician, Diagnostic Devices Branch, Division of Biostatistics, Office of Surveillance and Biometrics, CDRH, FDA

Role of the Clinical Laboratory Improvement Amendments (CLIA) Program (PDF)
Presented by: James Cometa, Team Leader/Program Analyst, Centers for Medicare & Medicaid Services, Survey and Certification Group, Division of Laboratory Services

Publications

Technology Assessment and Roadmap for the Emergency Radiation Dose Assessment Program March 2005 (PDF)
U.S. Department of Homeland Security, Science and Technology

back to top

Highlights

RFA-09-036: Centers for Medical Countermeasures Against Radiation (U19)

BAA-NIAID-DAIT-NIHAI2009051: Development of Oral Radionuclide Decorporation Agents for Use in Radionuclide Decorporation in Radiological Emergencies

BAA-NIAID-DAIT-NIHAI2009060: Development of Oral Form of Diethylenetriaminepentaacetate (DTPA) for Use in Radionuclide Decorporation – Radiological Emergency

PA-09-093: Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44]).  Standard SBIR receipt dates.

Solicitation: BAA-BARDA-09-34: BARDA Broad Agency Announcement for the Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures

Radiological Science in the Context of Radiological Terrorism—September 30, 2009, Hyatt Regency, Bethesda, MD.  Registration required.

See Also

  • Radiological and Nuclear Threats News Releases
  • Division of Allergy, Immunology, and Transplantation (DAIT)
  • Biodefense—The NIAID Biodefense Web site includes biodefense-related information for biomedical researchers, the public, and the media.

  • Highlights

    RFA-09-036: Centers for Medical Countermeasures Against Radiation (U19)

    BAA-NIAID-DAIT-NIHAI2009051: Development of Oral Radionuclide Decorporation Agents for Use in Radionuclide Decorporation in Radiological Emergencies

    BAA-NIAID-DAIT-NIHAI2009060: Development of Oral Form of Diethylenetriaminepentaacetate (DTPA) for Use in Radionuclide Decorporation – Radiological Emergency

    PA-09-093: Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44]).  Standard SBIR receipt dates.

    Solicitation: BAA-BARDA-09-34: BARDA Broad Agency Announcement for the Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures

    Radiological Science in the Context of Radiological Terrorism—September 30, 2009, Hyatt Regency, Bethesda, MD.  Registration required.

    See Also

  • Radiological and Nuclear Threats News Releases
  • Division of Allergy, Immunology, and Transplantation (DAIT)
  • Biodefense—The NIAID Biodefense Web site includes biodefense-related information for biomedical researchers, the public, and the media.